Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Cifenline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.79 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.79 |
| ▸ | AR | P10275 | 1/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | SCN1A | P35498 | 1/20 | 0.79 |
| ▸ | SCN4A | P35499 | 1/20 | 0.79 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.79 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.79 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.79 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.79 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.79 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.79 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.79 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.79 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.79 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.79 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cifenline SCHEMBL122806 | 0.89 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL23712302 | 0.89 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL23712274 | 0.89 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL121044 | 0.87 | CACNA1F (0.79) | CACNA1FARPDE4ASCN1ASCN4A | |
| Fumaric Acid SCHEMBL10760662 | 0.68 | NISCH (0.52) | LMNASMN1; SMN2RAB9AADRA2AADRA2B | |
| Fumaric Acid SCHEMBL9868088 | 0.65 | LMNA (0.43) | LMNASMN1; SMN2RAB9A | |
| Maleic Acid SCHEMBL9868080 | 0.65 | LMNA (0.43) | LMNASMN1; SMN2RAB9A | |
| SCHEMBL10467674 | 0.64 | LMNA (0.41) | LMNAMAOB | |
| SCHEMBL10467989 | 0.64 | LMNA (0.41) | LMNAMAOB | |
| SCHEMBL10467987 | 0.64 | LMNA (0.41) | LMNAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | claimed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12486237-B2 | Polymorphic form of (-)-cibenzoline succinate | CELLTRION INC. (KR) | 2025-12-02 | — | — | US | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230088511-A1 | Polymorphic Form of (-)-Cibenzoline Succinate | CELLTRION INC. (KR) | 2023-03-23 | — | — | US | disclosed |
| US-20230088511-A1 | Polymorphic Form of (-)-Cibenzoline Succinate | CELLTRION INC. (KR) | 2023-03-23 | — | — | US | disclosed |
| US-20230040902-A1 | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | CELLTRION INC. (KR) | 2023-02-09 | — | — | US | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3858816-A4 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2022-06-15 | — | — | EP | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNH2 4204/4885CACNA1F 2950/4885AR 3548/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | KCNH2 1902/4885CACNA1F 386/4885AR 1072/4885 |
| US-20230088511-A1 | Polymorphic Form of (-)-Cibenzoline Succinate | SDHA, SDHB, ALDH5A1 | KCNH2 1975/4885CACNA1F 300/4885AR 2420/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNH2 4204/4885CACNA1F 2950/4885AR 3548/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | KCNH2 4204/4885CACNA1F 2950/4885AR 3548/4885 |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | SARS1, EIF2AK2, ACE2 | KCNH2 3255/4885CACNA1F 3929/4885AR 4779/4885 |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | MKI67, CDK4, CDKN1A | KCNH2 4100/4885CACNA1F 3275/4885AR 2003/4885 |
| US-20230040902-A1 | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | CEL, SLC6A12, SLC6A1 | KCNH2 997/4885CACNA1F 130/4885AR 3876/4885 |
| US-12486237-B2 | Polymorphic form of (-)-cibenzoline succinate | SDHA, SDHB, ALDH5A1 | KCNH2 2029/4885CACNA1F 308/4885AR 2526/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | KCNH2 450/4885CACNA1F 32/4885AR 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.